Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia
Abstract
The aim was to assess the cost-effectiveness of cariprazine compared to second-generation antipsychotics in the treatment of schizophrenia for patients with negative symptoms in Hungary. To assess the cost-effectiveness of cariprazine, a deterministic 8-health state Markov cohort model was built. The analysis was performed from a third-party payer perspective. Data were gathered from relevant sources of the scientific literature and public...
Paper Details
Title
Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia
Published Date
Mar 1, 2019
Journal
Volume
8
Issue
1
Pages
84 - 91
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History